Last €5.54 EUR
Change Today +0.084 / 1.54%
Volume 800.0
NNF1 On Other Exchanges
Symbol
Exchange
Frankfurt
As of 11:19 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (NNF1) Snapshot

Open
€5.48
Previous Close
€5.45
Day High
€5.57
Day Low
€5.26
52 Week High
06/30/14 - €9.33
52 Week Low
03/31/14 - €2.79
Market Cap
2.2B
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
405.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MANNKIND CORP (NNF1)

mannkind corp (NNF1) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

265 Employees
Last Reported Date: 03/3/14
Founded in 1991

mannkind corp (NNF1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $718.9K
Founder and Executive Chairman
Total Annual Compensation: $824.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $440.8K
Chief Operating Officer
Total Annual Compensation: $459.1K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $387.4K
Compensation as of Fiscal Year 2013.

mannkind corp (NNF1) Key Developments

MannKind Corp. Announces Management Changes

MannKind Corporation announced that Alfred Mann, the company's founder, retired from his role as Chief Executive Officer effective January 9, 2015 and will transition to Executive Chairman. Mr. Mann intends to remain engaged with the company in business matters, including those relating to development and financing of the company's future therapies. On January 9, 2015, the company's Board of Directors appointed Hakan Edstrom, current President of the company, as the new Chief Executive Officer of the company. Mr. Edstrom concurrently resigned as Chief Operating Officer but continues to serve as President. Mr. Edstrom has served as MannKind's President and as a member of the Board of Directors since 2001. From 2001 until his appointment as Chief Executive Officer, he also served as the Chief Operating Officer of the company. Prior to joining the company, Mr. Edstrom was with Bausch & Lomb Inc. and prior to that with Pharmacia Corporation. Mr. Edstrom was recruited to Bausch & Lomb upon its acquisition of Chiron Ophthalmics and Storz Surgical Instrument Company. His responsibility was to merge the two companies' global operations and integrate them into Bausch & Lomb's global structure. Following the success of this combination, Mr. Edstrom was given responsibility for all of the Bausch & Lomb businesses in the North America region. The Board of Directors appointed Juergen A. Martens, Ph.D. as Chief Operating Officer.

MannKind Earns $50 Million in Milestone Payments from Sanofi

MannKind Corporation announced that it has earned a total of $50 million in milestone payments in connection with the satisfaction of manufacturing milestones specified in its collaboration and licensing agreement with Sanofi. Pursuant to the agreement, MannKind previously received a $150 million upfront payment and is eligible to earn up to $725 million in further development, regulatory and sales milestones, and is also eligible to receive a share of profits on sales of Afrezza.

MannKind Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 01:30 PM

MannKind Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 01:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NNF1:GR €5.54 EUR +0.084

NNF1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NNF1.
View Industry Companies
 

Industry Analysis

NNF1

Industry Average

Valuation NNF1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit www.mannkindcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.